As such, PARP inhibitors (PARPis) were introduced into clinical practice, serving as a key targeted therapy option through synthetic lethality in the treatment of cancers with homologous recombination repair deficiency (HRD). This evidence concerns the gene PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome.